![]() |
|
|
Vol. 62, Issue 1, 102-109, July 2002
Leukaemia Research Fund Molecular Pharmacology Specialist
Programme, Cancer Research Unit (S.A.C., L.A.H., M.L., E.C.M., L.M.,
A.G.H.), and Medical Molecular Biology Group (C.P.F.R.), Medical
School, Newcastle University, Newcastle-upon-Tyne, UK
Although the thiopurine drugs 6-mercaptopurine (6-MP) and 6-thioguanine
(6-TG) are well established agents for the treatment of leukemia,
controversies remain regarding their main mode of action. Previous
evidence has suggested that although 6-TG exerts a cytotoxic effect
through incorporation of 6-thioguanine nucleotides into newly
synthesized DNA (DNA-TGN), an important component of the mode of action
of 6-MP is inhibition of purine de novo synthesis (PDNS) through the
production of S-methyl-thioinosine 5'-monophosphate (MeTIMP), not formed in cells exposed to 6-TG. We have shown that thiopurine methyltransferase (TPMT) modulates this effect. By transfection of the human TPMT gene using an
inducible system to produce a 3.8-fold increase in TPMT activity in the
ecdysone receptor 293 embryonic kidney cell line, we demonstrated a
4.4-fold increase in sensitivity to 6-MP. This was associated with a
rise in intracellular levels of MeTIMP but a decrease in levels of DNA-TGN. In contrast, induction of TPMT produced a 1.6-fold decrease in
sensitivity to 6-TG, a decrease in levels of DNA-TGN, and an increase
in levels of methylated thioguanosine monophosphate. Exposure of cells
to equitoxic doses of drug showed similar incorporation of DNA-TGN for
6-TG but for 6-MP significantly reduced DNA-TGN in TPMT-induced
compared with uninduced cells. For equitoxic doses of 6-MP, equivalent
levels of MeTIMP correlated with equivalent amounts of PDNS. These
observations suggest that intracellular TGN levels do not give an
accurate reflection of cytotoxic potential in patients treated with
6-MP, because different levels of DNA-TGN may be associated with
equitoxic effects.
This article has been cited by other articles:
![]() |
S. Hoover and R. Striker Thiopurines inhibit bovine viral diarrhea virus production in a thiopurine methyltransferase-dependent manner J. Gen. Virol., April 1, 2008; 89(4): 1000 - 1009. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Karran Thiopurines, DNA damage, DNA repair and therapy-related cancer Br. Med. Bull., February 2, 2007; (2007) ldl020v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
U Hindorf, M Lindqvist, C Peterson, P Soderkvist, M Strom, H Hjortswang, A Pousette, and S Almer Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease Gut, October 1, 2006; 55(10): 1423 - 1431. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Gardiner and E. J. Begg Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice Pharmacol. Rev., September 1, 2006; 58(3): 521 - 590. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Arenas, G. Simpson, C. M. Lewis, E.-M. Shobowale-Bakre, E. Escuredo, L. D. Fairbanks, J. A. Duley, A. Ansari, J. D. Sanderson, and A. M. Marinaki Genetic Variation in the MTHFR Gene Influences Thiopurine Methyltransferase Activity Clin. Chem., December 1, 2005; 51(12): 2371 - 2374. [Full Text] [PDF] |
||||